Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted Biogen’s applications for a higher dose regimen of spinal muscular atrophy (SMA) treatment Spinraza ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

The two other SMA stalwarts on the market, Biogen’s oligonucleotide Spinraza and Novartis’ gene therapy Zolgensma, are delivered intrathecally (into the cerebrospinal fluid around the spinal ...

focusing on candidates for neurological disorders like multiple sclerosis and SMA. Biogen meanwhile is also pursuing other avenues of RNA drug discovery and development, and in 2018 expanded the ...

Exercise can make a significant difference for patients with SMA by working alongside other medical advancements to improve their quality of life.

Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...

The firm expanded its neurology portfolio beyond MS, including the blockbuster Spinraza for spinal muscular atrophy, or SMA, a rare neuromuscular disease. We see Biogen as a firm in transition ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...